Company’s 36-month beta value is 0.62.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for ENTA is 19.82M, and currently, short sellers hold a 13.11% ratio of that floaft. The average trading volume of ENTA on March 18, 2025 was 539.31K shares.
ENTA) stock’s latest price update
Enanta Pharmaceuticals Inc (NASDAQ: ENTA)’s stock price has decreased by -8.27 compared to its previous closing price of 6.65. However, the company has seen a -9.90% decrease in its stock price over the last five trading sessions. zacks.com reported 2025-02-14 that Enanta Pharmaceuticals (ENTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company’s earnings prospects. This might drive the stock higher in the near term.
ENTA’s Market Performance
Enanta Pharmaceuticals Inc (ENTA) has experienced a -9.90% fall in stock performance for the past week, with a -18.67% drop in the past month, and a -12.86% drop in the past quarter. The volatility ratio for the week is 8.97%, and the volatility levels for the past 30 days are at 8.78% for ENTA. The simple moving average for the last 20 days is -18.50% for ENTA stock, with a simple moving average of -40.04% for the last 200 days.
Analysts’ Opinion of ENTA
Many brokerage firms have already submitted their reports for ENTA stocks, with JP Morgan repeating the rating for ENTA by listing it as a “Underweight.” The predicted price for ENTA in the upcoming period, according to JP Morgan is $14 based on the research report published on August 09, 2023 of the previous year 2023.
Jefferies, on the other hand, stated in their research note that they expect to see ENTA reach a price target of $18, previously predicting the price at $49. The rating they have provided for ENTA stocks is “Hold” according to the report published on August 08th, 2023.
H.C. Wainwright gave a rating of “Buy” to ENTA, setting the target price at $56 in the report published on December 09th of the previous year.
ENTA Trading at -1.64% from the 50-Day Moving Average
After a stumble in the market that brought ENTA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.73% of loss for the given period.
Volatility was left at 8.78%, however, over the last 30 days, the volatility rate increased by 8.97%, as shares sank -14.57% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.09% upper at present.
During the last 5 trading sessions, ENTA fell by -9.90%, which changed the moving average for the period of 200-days by -48.87% in comparison to the 20-day moving average, which settled at $7.49. In addition, Enanta Pharmaceuticals Inc saw 6.09% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ENTA starting from Luly Jay R., who purchase 45,000 shares at the price of $5.69 back on Feb 12 ’25. After this action, Luly Jay R. now owns 846,638 shares of Enanta Pharmaceuticals Inc, valued at $256,050 using the latest closing price.
Kieffer Tara Lynn, the Chief Product Strategy Officer of Enanta Pharmaceuticals Inc, sale 2,283 shares at $8.06 during a trade that took place back on Dec 06 ’24, which means that Kieffer Tara Lynn is holding 29,305 shares at $18,401 based on the most recent closing price.
Stock Fundamentals for ENTA
Current profitability levels for the company are sitting at:
- -1.66 for the present operating margin
- 0.99 for the gross margin
The net margin for Enanta Pharmaceuticals Inc stands at -1.58. The total capital return value is set at -0.37. Equity return is now at value -69.10, with -27.00 for asset returns.
Based on Enanta Pharmaceuticals Inc (ENTA), the company’s capital structure generated 0.34 points at debt to capital in total, while cash flow to debt ratio is standing at -1.23. The debt to equity ratio resting at 0.51. The interest coverage ratio of the stock is -11.66.
Currently, EBITDA for the company is -104.51 million with net debt to EBITDA at 0.28. When we switch over and look at the enterprise to sales, we see a ratio of 1.55. The receivables turnover for the company is 8.63for trailing twelve months and the total asset turnover is 0.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.47.
Conclusion
In a nutshell, Enanta Pharmaceuticals Inc (ENTA) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
